The estimated Net Worth of Ajay Patel is at least 413 千$ dollars as of 12 May 2024. Mr Patel owns over 38,017 units of Assertio stock worth over 217,514$ and over the last 3 years he sold ASRT stock worth over 195,512$.
Mr has made over 12 trades of the Assertio stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 38,017 units of ASRT stock worth 48,282$ on 12 May 2024.
The largest trade he's ever made was exercising 238,017 units of Assertio stock on 12 May 2023 worth over 302,282$. On average, Mr trades about 33,362 units every 68 days since 2021. As of 12 May 2024 he still owns at least 171,271 units of Assertio stock.
You can see the complete history of Mr Patel stock trades at the bottom of the page.
Ajay Patel is the Sr. VP & Chief Accounting Officer at Assertio.
Mr Patel is 37, he's been the Sr. VP & Chief Accounting Officer of Assertio since . There are 2 older and no younger executives at Assertio. The oldest executive at Assertio Holdings, Inc. is Paul Schwichtenberg, 50, who is the Sr. VP & CFO.
Ajay's mailing address filed with the SEC is ASSERTIO HOLDINGS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST, IL, 60045.
Over the last 4 years, insiders at Assertio have traded over 6,616,337$ worth of Assertio stock and bought 68,828 units worth 87,071$ . The most active insiders traders include Group L.P.Crg Partners Iii ...、Timothy P Walbert、Daniel A. Peisert. On average, Assertio executives and independent directors trade stock every 21 days with the average trade being worth of 278,566$. The most recent stock trade was executed by Jeff L Vacirca on 11 June 2024, trading 10,000 units of ASRT stock currently worth 11,100$.
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Assertio executives and other stock owners filed with the SEC include: